Table 1.
Design Features of Contributing Studies
| Study Acronym or First Author | Location | Year of Baseline, Range | Study Quality, NOS | Mean Age, y | Male Sex, % | Osteoprotegerin Assay Type (Manufacturer) | Sample Type |
|---|---|---|---|---|---|---|---|
| Populations with diabetes mellitus at baseline | |||||||
| Anand17 | United Kingdom | NR | 7 | 52.7 | 60.6 | ELISA (Biomedica) | Plasma |
| FINNDIANE18 | Finland | 1997–2004 | 8 | 36.9 | 49.8 | IFMA (R&D Systems) | Serum |
| Populations with kidney disease at baseline | |||||||
| ALERT19, a | Multicenter | 1997 | 7 | 49.6 | 65.8 | ELISA (Biomedica) | Serum |
| CRISIS20 | United Kingdom | 2002–2010 | 6 | 63.8 | 61.8 | ELISA (BioVendor) | Plasma |
| Kuzniewski21 | Poland | 2004 | 8 | 60.0 | 56.5 | ELISA (BioVendor) | Plasma |
| Nakashima22 | Japan | 2003 | 7 | 62.1 | 56.3 | ELISA (Immundiagnostik) | Plasma |
| Nishiura23 | Japan | 2000–2006 | 7 | 58.9 | 65.7 | ELISA (Immundiagnostik) | Serum |
| Speer24 | Hungary | 2004–2007 | 7 | 63.4 | 61.2 | ELISA (Immundiagnostik) | Serum |
| Yilmaz25 | Turkey | 2009–2013 | 7 | 48.9 | 51.9 | ELISA (RayBiotech) | Serum |
| Populations with preexisting heart disease at baseline | |||||||
| CLARICOR26, a | Denmark | 1999–2000 | 9 | 65.4 | 69.4 | IFMA (R&D Systems) | Serum |
| CORONA27, a | The Netherlands | 2003–2005 | 8 | 72.0 | 76.7 | ELISA (R&D Systems) | Plasma |
| Jono28 | Japan | 1999–2000 | 8 | 63.1 | 82.7 | ELISA (Cosmo Bio) | Serum |
| PEACE29, a | Multicenter | 1996–2000 | 6 | 63.7 | 81.0 | ELISA (R&D Systems) | Plasma |
| Pedersen (1)30 | Norway | 2000–2001 | 9 | 62.0b | 71.9 | ELISA (R&D Systems) | Serum |
| Populations with recent acute coronary syndromes at baseline | |||||||
| MERLIN‐TIMI3631, a | Italy | 2004–2006 | 8 | 64.0 | 64.9 | IFMA (R&D Systems) | Plasma |
| OPTIMAAL32 | Multicenter | 1998–1999 | 9 | 67.8 | 70.3 | ELISA (R&D Systems) | Plasma |
| PLATO33, a | Multicenter | 2006–2008 | 6 | 62.0 | 71.6 | ELISA (NR) | Plasma |
| PRACSIS34 | Sweden | 1996–2001 | 9 | 65.0 | 70.7 | ELISA (R&D Systems) | Serum |
| Pedersen (2)35 | Denmark | 2006–2008 | 9 | 63.5 | 41.3 | IFMA (R&D Systems) | Plasma |
| Total | 1996–2013 | 7.6 | 60.9 | 68.3 | |||
Summary statistics are ranges, weighted means, or sums, as appropriate. ALERT indicates Assessment of Lescol in Renal Transplantation Study; CLARICOR, Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease; CORONA, Controlled Rosuvastatin Multinational Trial; CRISIS, Chronic Renal Insufficiency Standards Implementation Study; FINNDIANE, Finnish Diabetic Nephropathy Study; IFMA, immunofluorometric assay; MERLIN‐TIMI36, Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST‐Elevation Acute Coronary Syndromes Trial; NOS, Newcastle‐Ottawa scale; NR, not reported; OPTIMAAL, Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan; PEACE, Prevention of Events With Angiotensin Converting Enzyme Inhibition Trial; PLATO, Platelet Inhibition and Patient Outcomes Trial; PRACSIS, Prognosis and Risk in Acute Coronary Syndrome in Sweden.
Nested in clinical trial.
Median.